OK SB1844

Allows patients with life-threatening or severely debilitating illnesses to access individualized investigational treatments (including gene therapy and neoantigen vaccines) based on their genetic profile, after considering all FDA-approved options and providing written informed consent

Requires treatments to be provided through facilities operating under a Federalwide Assurance (FWA) for the Protection of Human Subjects; manufacturers may voluntarily provide treatments at no cost or charge patients for manufacturing costs

Excludes from coverage controlled substances illegal under federal law and any products derived from embryonic stem cells or abortion-related tissues

Grants immunity from civil liability to manufacturers and health care providers acting in good faith; prohibits licensing boards from taking action against providers solely for recommending these treatments

Does not require insurers, health plans, or government agencies to cover treatment costs; effective date November 1, 2026